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Introduction
People over the age of 75 years, an age group that is 
increasing,1 are at a substantially increased risk of 
cardiovascular disease (CVD) and age-related mor-
bidity and mortality compared with younger peo-
ple.2 Primary preventive measures remain important 
in this age group, both in terms of lifestyle modifica-
tion and drug treatment. Statins are the most widely 
used preventive drugs for CVD and are one of the 
most frequently used drug classes worldwide. 
However, their use is controversial in older people 
because there is significantly less evidence for this 
age group and the risk for statin-related harms 
increases with age, which could potentially offset 
their positive effects. The US Preventive Services 
Task Force concluded in a recent review that older 
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people are underrepresented in trials and there is 
insufficient evidence to draw a robust conclusion 
about the balance of benefits and harms of statins 
for primary prevention in this age group.3,4 A lim-
ited amount of evidence from trials and observa-
tional studies has, however, become available 
recently that demonstrated the limited effects of 
statins for reducing CVD or all-cause mortality in 
individuals aged 75 years or older.5–7 These results 
raise the question in which age group the expected 
benefits of statins outweigh the expected harms.
A previous benefit–harm balance study found that 
in people aged 40–74 years, the 10-year CVD risk 
at which to initiate statins was between 14% and 
22%, depending on age and sex, in order to achieve 
more benefits than harms from statin use.8 This is 
above the commonly used 7.5% or 10% 10-year 
CVD risk thresholds proposed to initiate statins for 
primary prevention in most guidelines issued by a 
number of different societies in cardiology;4,9 yet 
for most age groups, this figure is lower than the 
20% proposed threshold in general or family medi-
cine guidelines, including the German guideline.10 
The study demonstrated that the benefit–harm 
balance of statins is less favorable with increasing 
age as the risks of experiencing harms increases 
proportionally more than the absolute reduction in 
CVD risk. Increased risk of harms including type 2 
diabetes, cataracts, liver and kidney dysfunction, 
myopathy, and cognitive dysfunction– potential 
harms of statins– can be of increased concern for 
people over the age of 75 years because they poten-
tially contribute to increased frailty and disability. 
However, neither the previous study nor any other 
analysis, to the best of the authors’ knowledge, 
assessed the benefit–harm balance of statins for 
this specific age group. In addition, the previous 
study did not assess the effect of different patient 
preferences on the benefit harm balance. Therefore, 
the current study aimed to assess the benefit–harm 
balance of low to moderate dose statins in adults 
over the age of 75 years for primary prevention of 
CVD, to determine baseline CVD risk thresholds 
above which a net benefit is achieved, on average, 
and to assess how the risk thresholds vary accord-
ing to individual patient preferences.
Methods
Study design
We conducted a benefit–harm balance modeling 
study that included the following five standard 
steps.11 First, the exact question including the pop-
ulation of interest, intervention, comparator, and 
outcomes were specified. The population of inter-
est were individuals aged 75 years or older with no 
prior history of CVD. The intervention was low to 
moderate dose statins compared with no statin 
use. The benefit outcome of interest was CVD 
(composite of unstable angina, myocardial infarc-
tion [MI], and ischemic stroke), and the potential 
harm outcomes included myopathy and muscle 
weakness, type 2 diabetes, renal and hepatic dys-
function, cancer, cognitive impairment, hemor-
rhagic stroke, digestive distress, and cataracts. The 
outcomes were selected based on our previous sur-
vey and trial reports.12,13 Second, a systematic 
approach was followed to identify and select the 
most valid and applicable evidence for the target 
population, as described previously and further 
described in the following.11 The three key input 
parameters in the model include relative effect esti-
mates of statins on benefit and harm outcomes, 
baseline risks of outcomes (in people not using 
statins), and preference weighting for benefit and 
harm outcomes from a patient’s perspective. 
Third, the statistical analysis used was an exponen-
tial model to estimate the expected number of 
events for the benefit and harm outcomes in peo-
ple using statins over a 10-year horizon versus not 
using statins, that also took into account patient 
preferences, competing risks, and statistical uncer-
tainty to produce a single index indicating the 
benefit–harm balance. This method was first deve-
loped by Gail and colleagues14 from the National 
Cancer Institute (Gail/NCI) to assess the net ben-
efit of tamoxifen in preventing breast cancer. We 
extended this approach to fit the research question, 
in particular to determine the risk thresholds above 
which the benefits of statins outweigh their harms 
(see the analysis).8 Fourth, sensitivity analyses 
were conducted to test alternative assumptions as 
described further below. Finally, the benefit–harm 
balance results were interpreted.
Parameters required for benefit–harm balance 
assessment
Treatment effect estimates. We searched for pri-
mary prevention trials specific to older people to 
derive the most valid, applicable, and precise evi-
dence for the effects of statins on CVD. We also 
searched for large and high-quality observational 
studies in anticipation of scarce evidence from trials 
related to the target population. We could not iden-
tify a primary prevention trial that only included 
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people aged 75 years or older. Two trials, the Study 
Assessing Goals in the Elderly (SAGE) and the 
pravastatin in elderly individuals at risk of vascular 
disease study (PROSPER), included people over 
the age of 65 years. However, SAGE was a second-
ary prevention trial and PROSPER was conducted 
in mixed primary and secondary prevention popu-
lations.15,16 We identified a recent and high-quality 
systematic review that provided the most valid and 
applicable estimates on the beneficial effects of 
statins for primary prevention of CVD in people 
over the age of 75 years, which pooled individual 
patient data from multiple trials.7 The majority of 
the data in this review primarily came from four tri-
als,17 including the Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack 
Trial–Lipid-Lowering Trial (ALLHAT-LLT) that 
tested 40 mg/dl pravastatin daily versus placebo,18 
the Anglo-Scandinavian Cardiac Outcomes Trial–
Lipid Lowering Arm (ASCOT-LLA) that evalu-
ated 10 mg/dl atorvastatin daily versus placebo,19 
the Justification for Use of Statins in Prevention: An 
Intervention Trial Evaluating Rosuvastatin (JUPI-
TER) that evaluated 20 mg/dl rosuvastatin daily 
compared with placebo,20 and the Heart Outcomes 
Prevention Evaluation (HOPE-3) trial that evalu-
ated outcomes of 10 mg/dl rosuvastatin daily com-
pared with placebo.21 The ALLHAT-LLT study 
had a higher proportion of patients with diabetes 
among those without prior CVD, but this trial 
contributed the least amount of data among the 
four trials (see the original publication17).
We did not find any trial that included only people 
over the age of 75 years that assessed the harm out-
comes. The systematic review described above also 
did not report on harm outcomes except cancer, 
but the effect on cancer was for mixed popula-
tions.7,17 While a post hoc subgroup analysis of the 
JUPITER trial reported harm estimates for people 
aged 70–97 years,22 JUPITER evaluated moderate 
to high-dose rosuvastatin (20 mg/dl), which is 
unlikely to be used as a routine dose for primary 
prevention, particularly in older people. In addi-
tion, over 56% of the participants in the age group 
of 70–97 years were aged between 70 and 75 years,17 
which was not our target population. Therefore, 
we did not consider this trial as the only input data 
for the analysis in order not to overestimate the risk 
of harms. We relied on the four trials that tested 
low, moderate, and moderate–high doses.18,19,21,22 
Unfortunately, none of the studies reported on all 
of the harm outcomes consistently. This led to 
difficulties in including all harm outcomes in our 
analysis. We considered the harm outcomes if they 
were defined and measured consistently across the 
included trials. Finally, the included harm out-
comes were renal impairment, diabetes, myopa-
thy, and cancer. In addition, non-CVD mortality 
was included (i.e. deaths unrelated to statins) as a 
competing risk to take into account the increased 
death rates in older populations. If this was disre-
garded, it would overestimate the expected num-
ber of prevented or excess events.
Moreover, we considered observational studies for 
some of the harm outcomes, in particular for dia-
betes and cancer,5,6 and consolidated them with 
the above trials.8 That is, while trials are often 
considered as the gold standard to provide reliable 
effect estimates because they are usually powered 
to detect efficacy (here reduction in CVD),23 
observational studies are often more suitable to 
assess the harms of treatments.24 Therefore, we 
used the effect estimate for the reduction in CVD 
from trials only in the main analysis and performed 
a sensitivity analysis taking a combined effect for 
CVD reduction from more recently published 
large observational studies.5,6
Baseline risks. Baseline risks for the benefit and 
harm outcomes are required to estimate the abso-
lute number of prevented or excess events. We 
searched for large registries and observational stud-
ies that provide real-world baseline risks for people 
aged 75 years or older, rather than taking rates from 
trials (control arm). The baseline risk for CVD to 
initiate statins is what we aimed to determine from 
this study. However, we took empirical age- and 
sex-specific baseline risks for the harm outcomes, 
including diabetes, cancer, and competing risk for 
non-CVD mortality for Switzerland from the 
Global Burden of Disease (GBD) estimates,25 and 
renal impairment and myopathy from the UK 
General Practitioner database (summarized in 
Table 1).26 We chose to take data from Switzerland 
for some of the baseline risks because the outcome 
preferences were elicited there and the outcome 
risks were moderate in Switzerland, therefore avoid-
ing a number of extreme results. For the risks of 
renal impairment and myopathy, which were not 
available in the Swiss population, the rates from the 
UK did not represent extreme values because the 
source study only included moderate-to-severe 
cases (in addition, they were average, not age or sex 
specific rates).
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Outcome preferences. To balance the CVD events 
prevented by statin use against the excess number 
of harm events, outcomes need to be weighted 
according to their relative importance or patient 
preferences. We considered patient preferences 
from a best-minus-worst scaling (BWS) survey 
conducted in Switzerland to inform the choice of 
weightings on selected outcomes.12 We used both 
aggregated patient preferences so as to determine 
average risk thresholds as well as individual patient 
preferences in order to assess risk threshold varia-
tion.28 We used average preference weightings in 
the main analysis on a 0–1 scale estimated using 
the surface under the cumulative ranking curve (a 
network meta-analysis comparing the importance 
of outcomes).29 This method cannot estimate 
preferences for individuals. We calculated individ-
ual preference values (from 120 participants in the 
BWS survey) using best-minus-worst score (i.e., 
the number of times an outcome was selected as 
most worrisome minus the number of times it was 
selected as least worrisome across choice sets) and 
normalized them according to relative probabili-
ties (Appendix Figure 1).
Of note, the preference for the benefit outcome was 
originally determined for each component of CVD 
events,12 not for CVD composite outcomes because 
of its wide range of manifestations that creates chal-
lenges when determining preferences from individ-
ual patients. We generated preference values for the 
CVD composite endpoint by taking into account 
the preference values of each CVD component and 
their frequency in the general populations (e.g., 
mild-to-moderate MIs were more frequent than 
severe or fatal MIs). The resulting preference for 
the composite CVD used in this analysis was equiv-
alent to the weight of a moderate MI.
Subgroups. Our previous work highlighted differ-
ent risk thresholds based on age and sex.8 There-
fore, the risk thresholds in this analysis were 
determined for men and women aged 75–79 years 
and 80–84 years, separately taking the age and sex 
specific baseline risks and treatment effects into 
account. We did not include people aged 85 years 
or older in order to avoid inadequate conclusions 
because there was a very limited amount of evi-
dence available for this age group.
Statistical analysis
The statistical analysis methods are briefly pre-
sented here, and the detailed methods are 
available in the literature.8 We calculated the 
expected number of prevented CVD events and 
excess harm events among 10,000 people treated 
with statins over a 10-year horizon versus an iden-
tical cohort not treated with statins. We calcu-
lated event numbers for men and women 
separately in different age groups, and at differ-
ent 10-year baseline risks for CVD (1%, 2%, 3% 
etc.) until benefits outweighed harms. We 
weighted the differences in the expected number 
of prevented CVD events and excess harm events 
using the respective preference weightings and 
summed them across all outcomes to obtain a 
single benefit–harm balance index. We per-
formed the analysis for 100,000 repetitions for 
each subgroup, considering the statistical uncer-
tainty for each input parameter, to generate a dis-
tribution of the benefit–harm balance index. 
From this distribution, we calculated the proba-
bility that the index was positive for the different 
subgroups. Then, the defined net benefit was 
determined; i.e., the benefits outweighed harms, 
when the probability for the index being positive 
was at least 60%. This means that in 60% of the 
100,000 repetitions, statins would be more likely 
to provide a net benefit compared with not taking 
statins. We defined net harm, or harms out-
weighed benefits, if the probability for the index 
being positive was less than 40%. Probabilities 
between 40% and 60% represented neither net 
benefit nor net harm.
Moreover, while it is important to estimate the 
clinical relevance of the thresholds, the absolute 
value of the benefit–harm balance index is diffi-
cult to interpret because it is a composite output 
of multiple parameters. In theory, the index can 
be interpreted as the number of prevented fatal 
CVD cases (with a maximum preference weight 
of 1.0) in 10,000 people treated with statins. 
However, we converted the index back into CVD 
composite outcome and moderate MI (i.e., divid-
ing the index by the moderate MI preference 
weight), but preferred to report the prevented 
events equivalent to moderate MI with taking 
statins for the sake of effective communication 
(unlike CVD owing to its wide range of manifes-
tations). We present these absolute events in 
10,000 people with their uncertainty intervals 
based on the 5th and 95th percentiles derived 
from the respective distribution of benefit–harm 
balance index. This interpretation of the net pre-
vented MI events should apply to the positive 
index only, not for the negative index where there 
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6 journals.sagepub.com/home/taj
would be no expected benefit. We performed all 
analyses using R version 3.3.2 (R Foundation for 
Statistical Computing).30
Sensitivity analyses
We determined the thresholds using an alterna-
tive assumption by taking all treatment effects 
from trials only (i.e. excluding observational stud-
ies for diabetes and cancer estimates). In addi-
tion, we ran the analysis with combined effect 
estimates of statins on CVD from trials (risk ratio, 
0.922; 95% CI 0.773–1.099) and large and valid 
observational studies conducted from the data-
base of the Catalan primary care system (hazard 
ratio 0.94; 95% CI 0.86–1.04) and French health 
care system database (hazard ratio 0.93; 95% CI 
0.89–0.96).5,6 The hazard ratio was approximated 
to a risk ratio using a conversion equation.31
Ethics
This study was based on published and aggre-
gated data for which no ethical approval was 
needed.
Results
Expected outcome events
The expected numbers of CVD and harm out-
comes, with their uncertainty intervals in people 
treated with statins versus not treated are pre-
sented in Tables 2–5. The absolute expected 
prevented CVD events over 10 years of taking 
statins were higher in people at high risk of CVD, 
increasing from 6 in 10,000 people at a 1% 
10-year baseline CVD risk to 153 in 10,000 peo-
ple with a 25% 10-year baseline CVD risk. As a 
result, the magnitude of benefit increases across 
the risk spectrum, with people at higher risk deriv-
ing greater benefit. The expected number of harm 
events was assumed to be similar across the CVD 
risk spectrum. In 10,000 people taking statins 
daily for 10 years, the absolute expected excess 
risk of developing myopathy was 18 for men and 
17 for women, and 12 in men and 10 in women 
for renal impairment, the same in both age 
groups. However, excess type 2 diabetes events 
were marginally different between the age groups 
(because of differences in baseline risks), with 
44 per 10,000 men aged 75–79 years (35 events in 
ages 80–84 years) and 42 per 10,000 women aged 
75–79 years (35 events in ages 80–84 years). 
Similarly, the expected number of cancer events 
was 32 per 10,000 men aged 75–79 years (33 
events in ages 80–84 years) and 24 per 10,000 
women aged 75–79 years (25 events in ages 
80–84 years).
CVD risk thresholds and absolute net benefit 
events
Weighting the prevented CVD events against the 
harm outcomes yielded the benefit–harm index 
(Tables 2–5). Based on the average preference 
values, statins were more likely (with a probability 
of 60% or above) to provide a net benefit for older 
people at baseline 10-year CVD risk threshold of 
24% and 25% in men aged 75–79 years and 80–
84 years, respectively. The threshold for women 
was 21% for both age groups (Tables 2–5). In 
other words, older people with baseline CVD risk 
lower than those thresholds were not likely to 
obtain a net benefit from taking statins. The cor-
responding absolute net prevented events at the 
determined thresholds, expressed in terms of 
moderate MI events, were 65 (5th and 95th per-
centiles, –419 to 531) in 10,000 men aged 75–
79 years and 68 (5th and 95th percentiles, –406 to 
527) in men aged 80–84 years. These events were 
similar in women; that is, taking statins daily for 
10 years would prevent 62 events equivalent to 
moderate MI (5thand 95the percentiles, –352 to 
456) in 10,000 women aged 75–79 years and 64 
(5th and 95th percentiles, –383 to 484) in 10,000 
women aged 80–84 years with a baseline CVD 
risks of 21% (Tables 2–5).
Preference-sensitivity of thresholds
The thresholds varied by individual preferences 
regardless of whether we took estimates from trials 
only or combined effect from observational stud-
ies. For each set of preference values derived from 
the 120 BWS survey respondents, we repeated the 
entire analyses and, therefore, derived 120 esti-
mates of the benefit–harm balance indices and risk 
thresholds for the net benefit for each subgroup. 
The thresholds ranged from 11% to 59% 10-year 
CVD risk in men and from 10% to 59% 10-year 
CVD risk in women (Figure 1). The interquartile 
ranges (IQRs) of the thresholds in men were 
between 21% and 33% for ages 75–79 years and 
between 23% and 36% for ages 80–84 years. The 
corresponding IQRs in women were between 20% 
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and 32% for ages 75–79 years and between 21% 
and 32% for ages 80–84 years. A number of indi-
vidual’s preference values resulted in even higher 
thresholds. For example, 10 out of 120 people in 
each of the two age groups had very low prefer-
ence values for CVD but higher values for the 
harm outcomes resulting in higher-risk thresholds 
or no net benefit at all. In addition, the opposite 
was true with individuals giving increased weight 
to CVD than to harm outcomes, which resulted in 
very low-risk thresholds.
Sensitivity analyses
In the main analysis, the estimates for the risk of 
diabetes and cancer were consolidated from both 
trials and observational studies. Rejecting the 
treatment estimates for these two outcomes from 
observational studies, statins showed net benefit 
at 23% and 21% 10-year CVD risk thresholds for 
men aged 75–79 years and 80–84 years, respec-
tively, and 21% and 19% 10-year CVD risk for 
women aged 75–79 years and 80–84 years, respec-
tively. The thresholds were slightly lower than 
those in the main analysis. This can be explained 
because cancer incidence was dropped from this 
analysis as a harm outcome as there was no treat-
ment effect in the included trial data. In addition, 
the risk decreases for diabetes with age in the gen-
eral population, particularly over the age of 
75 years, resulted in lower absolute excess risk 
and, therefore, affected the thresholds toward 
lower values in the older age group (80–84 years) 
than the younger age group (75–79 years), which 
was in contrast to the main analysis.
In addition, another sensitivity analysis in which 
we used combined effect estimates for CVD from 
trials and observational studies, instead of from 
trials only, revealed slightly higher thresholds 
than the main analysis with 27% and 28% 10-year 
CVD risk for men aged 75–79 years and 80–
84 years, respectively, and 24% for both age 
groups in women. Risk thresholds remained pref-
erence-sensitive across all analyses.
Discussion
This study found that in a primary prevention 
population aged 75 years or older and with mod-
erate baseline harm risks, statin use is more likely 
to provide a net benefit if the baseline CVD risk is 
at least 24% in men and 21% in women. However, 
when taking into account variation in preferences 
for benefit and harm outcomes between individu-
als, the thresholds for a net benefit may be signifi-
cantly increased or decreased on an individual 
level. This indicates that the benefit–harm bal-
ance of statins is highly preference-sensitive and 
that the average risk thresholds derived in this 
study can only give a limited amount of guidance, 
and patient-centered decision-making needs to 
take individual preferences into account.
Figure 1. The 10-year CVD risk threshold variation taking preferences of CVD and statin-related harm 
outcomes taken from individuals.
A small fixed noise was added to the threshold points in the figure for visibility. CVD, cardiovascular disease.
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Guideline developers have understandably been 
hesitant to make recommendations on the pre-
scription of statins as a primary preventive meas-
ure for people over the age of 75 years because of 
the limited number of randomized controlled trial 
data available for this age group. With the recent 
data from a meta-analysis of individual patient 
data from trials and two large observational stud-
ies, there is now an increased amount of evidence 
on the effects of statins on CVD in this popula-
tion.5–7 The smaller observed treatment effect of 
statins on CVD in people over the age of 75 years 
of only 8% relative risk reduction, as compared 
with 24–26% in younger adults,7,13 is an impor-
tant reason why the 10-year CVD risk thresholds 
for an overall beneficial effect is quite high and 
well above risk thresholds recommended by a 
number of guidelines.9,32,33
Despite the recently available evidence on the 
effect of statins on CVD in older people,7 it is 
probable that additional evidence will change the 
current estimates of the benefit–harm balance 
(e.g., the ongoing STAREE trial in the elderly 
may provide further evidence).34 It is likely that 
the thresholds could be even higher because we 
did not include some of the harm outcomes in our 
analysis owing to a lack of evidence (i.e., hepatic 
dysfunction, cataracts, cognitive loss, and gastro-
intestinal problems).7,13 To overcome the limited 
amount of data, we combined evidence from 
observational studies with the trial data on diabe-
tes and cancer.23 If only the trial data are relied 
on and the observational data are excluded, the 
thresholds showed slightly lower risk thresholds 
because no effect of statins on cancer was observed 
in the included trials. In addition, because the 
absolute treatment effects as well as the benefit–
harm balance are highly dependent on the base-
line risks, using more valid and precise baseline 
risks in the model could change the benefit–harm 
balance estimates.11 Finally, it is also possible that 
additional preference-elicitation surveys could 
obtain different average weightings for older peo-
ple for the outcomes depending how the deci-
sional context is framed and depending on the 
methods used to determine preferences and the 
age of the population studied.
Our work demonstrates that individual prefer-
ences have a substantially greater effect on the 
benefit–harm balance than specific additional 
pieces of evidence. This has important implica-
tions for guideline developers. Despite the official 
endorsement for considering patient preferences, 
guidelines commonly issue only a single or few 
recommendations that are independent of patient 
preferences, values, and context.35 However, even 
the most valid and largest trials or observational 
studies will not be conclusive as to whether the 
intervention will be worthwhile for an individual 
patient unless the perspectives of patients are con-
sidered, including their preferences. We had the 
opportunity to consider combinations of prefer-
ences from 120 people and estimate the benefit–
harm balance for each combination. As can be 
expected, the benefit–harm balance of statins for 
primary prevention in older people varied dramat-
ically across the combinations of preferences. As a 
consequence, a one-size-fits-all recommendation 
is not appropriate for such a preference-sensitive 
decision, and according to the guidance of the 
GRADE Working Group, strong recommenda-
tions should not be issued either for or against 
statins in such a situation.36 Depending on the 
context in which the recommendations are devel-
oped (i.e., considering specific population base-
line risks or other factors), weak recommendations 
for statins could be issued for older people at 
10-year CVD above 21% or 24%. These recom-
mendations should acknowledge that depending 
on the individual’s preferences, this threshold 
could be significantly lower or higher. Tailoring 
recommendations to individual patients could be 
supported by using decision aids that consider 
individual patient baseline risks and preferences.
Prescribing statins to older people needs further 
careful handling because simply focusing on the 
total absolute risk could lead to overtreatment. 
Older people could easily meet the risk thresholds 
just because of their age, which is a strong inde-
pendent, but nonmodifiable risk factor.37 Instead, 
it is important to assess the modifiability of the 
underlying risk factors, including cholesterol lev-
els, diabetes, hypertension, smoking, and vascu-
lar inflammation because statins do not have any 
benefit otherwise.6 Nevertheless, how diabetes 
predicts CVD in people taking statins is not clear 
from the current literature; that is, studies show 
that statin therapy reduces the risk for CVD but it 
could increase blood sugar as an adverse effect 
and, therefore, increase the risk for CVD where 
the effects may cancel each other out.5,6,15 We did 
not determine a risk threshold specifically for dia-
betes patients because considering such heteroge-
neous evidence in the analysis could be misleading. 
Our findings could apply to all people regardless 
HG Yebyo, HE Aschmann et al.
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of whether they have diabetes. However, it should 
be noted that patients with diabetes would still 
have an increased chance of being recommended 
for statins because diabetes strongly increases the 
baseline CVD risk score.
An important limitation of this study was that we 
could not consider all prespecified harm outcomes, 
as noted previously. In addition, obtaining valid, 
applicable, and precise effect estimates of the harm 
outcomes that were included was a challenge. 
Some of the estimates that were extrapolated from 
trials could have included people younger than 
75 years. However, the extrapolation was more 
likely to overestimate the net benefit in older people 
because it is expected that the harm outcomes are 
generally increased in older people because of 
frailty, comorbidities, and polypharmacy and drug–
drug interactions. In addition, the generalizability 
of the thresholds to other countries should be 
further investigated taking into consideration 
country-specific outcome risks. An additional limi-
tation is that we took the preferences from empiri-
cal research that included people mostly younger 
than 75 years.12 We can only speculate what the 
results in this older age group would be but it is 
possible that, as older people might not live long 
enough to receive long-term benefits, they would 
worry more about harm outcomes than younger 
people since the harm outcomes could affect their 
quality of life in the short term. This might have 
overestimated the net benefit. However, in the 
BWS survey there was no association between age 
and preferences. A strength of the survey is that 
preferences were elicited using lay descriptions that 
were constructed based on the clinical features, 
treatment options, and prognosis of the outcomes. 
As a result, the preferences were similar across the 
socioeconomically disparate environments of 
Switzerland and Ethiopia.12 In addition, the GBD 
study also found similar preferences across several, 
quite different countries.38 However, treatment 
preferences might vary depending on other factors 
that were not captured in the lay descriptions of our 
preference- eliciting survey, such as costs or access 
to care. Therefore, country-specific preference val-
ues may be required if consideration of such factors 
is warranted. However, it is probable that prefer-
ences vary between individuals in different coun-
tries and, most importantly, this study revealed that 
individual treatment thresholds are preference- 
sensitive and, thus, might differ notably from aver-
age population-level preferences
In conclusion, this study has demonstrated that the 
benefits of statins would be more likely to outweigh 
their harm in primary CVD prevention if the 
10-year risk of people over the age of 75 years is 
higher than 20%. However, these thresholds 
assume average preferences in a population. This 
study further demonstrated that the benefit–harm 
balance is highly dependent on individual prefer-
ences for benefit and harm outcomes. As a conse-
quence, guidelines should continue to be cautious 
when making population-level recommendations 
and should support individual decision-making 
taking into account individual modifiable risks and, 
probably most importantly, individual preferences.
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